Back to Results
First PageMeta Content
Selective serotonin reuptake inhibitors / Acetamides / Organofluorides / Treatment of bipolar disorder / Antidepressants / Agomelatine / Venlafaxine / Fluoxetine / Serotonin–norepinephrine reuptake inhibitor / Chemistry / Organic chemistry / Psychiatry


PUBLIC SUMMARY DOCUMENT Product: AGOMELATINE, tablet, 25mg, Valdoxan® Sponsor: Servier Laboratories (Australia) Pty Ltd Date of PBAC Consideration: March[removed]Purpose of Application
Add to Reading List

Document Date: 2015-03-06 00:23:40

Open Document

File Size: 383,86 KB

Share Result on Facebook

City

Trial / /

Company

AEs / Servier Laboratories (Australia) Pty Ltd / Servier Laboratories / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / /

IndustryTerm

treatment of depression / treatment of major depressive disorder / /

MedicalCondition

Montgomery-Asberg depression / major depressive disorder / Proposed Therapy Major depression / less sexual dysfunction / sleep disorders / dysfunction / depression / major depressive disorders / /

Organization

National Science Foundation / /

Position

First author / Governor / TGA clinical evaluator / /

Product

venlafaxine / fluoxetine / escitalopram / Valdoxan / HT2C / /

URL

http /

SocialTag